NDAC
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee meeting now tentatively scheduled for Dec. 1 to discuss an NDA in conjunction with agency's Antiviral Drugs Advisory Committee. Speculation for the product to be reviewed continues to center on SmithKline Beecham's Denavir cold sore medication